SEBI"s Unusual Ruling on Piramal Pharma Raises Questions for Listed Companies

The review order issued by the Securities and Exchange Board of India (SEBI) regarding Piramal Pharma is highly unusual. It deviates from standard regulatory practices by re-examining a previous ruling that cleared the company of alleged violations related to the non-disclosure of material events.

This raises questions about the implications for other listed companies, and legal experts are closely monitoring the situation to see if it will set a precedent for similar cases in the future.

Typically, review orders by SEBI result in increased penalties or further proceedings against the entities involved. However, in this case, Piramal Pharma has once again been exonerated by a whole-time member of SEBI.

Trending
Subcategory:
Countries:
Companies:
Currencies:
People:

Machinary offers a groundbreaking, modular, and customizable solution that provides advanced financial news and statistical analysis. Our platform goes beyond traditional quantitative analysis, offering users a comprehensive understanding of real-time market dynamics, event detection, and risk analysis.

Address

Newsletter

© 2025 by Machinary.com - Version: 1.0.0.0. All rights reserved

Layout

Color mode

Theme mode

Layout settings